BRD4-IN-11
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C40H37ClN4O5S3
- 分子量:785.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
BRD4 (BD1) 26.35 nM (IC50) |
BRD4 (BD2) 72.81 nM (IC50) |
BRD4-IN-11 (Compound 11r) exhibits inhibition of LX-2 cells[1].
BRD4-IN-11 (0.5-2.0 μM, 48 h) reduces the apoptosis rate, inhibits the expression of CDC25B, α-SMA, and c-Myc, and fibronectin in Carbon tetrachloride (CCl4) (HY-Y0298)-treated LO2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BRD4-IN-11 (15-30 mg/kg, p.o., once a day, 15 days) prevents lung fibrosis in Bleomycin (BLM) (HY-108345) induced pulmonary fibrosis (PF) model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CCl4-induced (1 mg/kg, i.p.) male C57BL/6J mice (6-7weeks old) hepatic fibrosis model[1]
-
Dosage:15 mg/kg, 30 mg/kg
-
Administration:p.o., once a day, 3 days
-
Result:Alleviated CCl4-induced liver fibrosis, reduced collagen deposition in liver tissue and the increased expression of fibrosis biomarkers (type I collagen and α-SMA) in CCl4-treated mice, and alleviated CCl4-induced massive hepatocyte apoptosis.
Reduced liver weight coefficient and AST, ALT and TG levels at 30 mg/kg.
Had a safer and more effective ameliorative effect on CCl4-induced organ toxicity than JQ-1 (HY-78695), and that high dose is more effective than low dose.
-
Animal Model:BLM-induced (2 mg/kg, injected into the trachea) male C57BL/6J mice (6-7weeks old) PF model[1]
-
Dosage:15 mg/kg, 30 mg/kg
-
Administration:p.o., once a day, 15 days
-
Result:Reduced lung coefficient (lung weight/body weight ratio) and hydroxyproline content (a specific marker of collagen deposition and fibrosis severity), indicating effective attenuation of fibrosis at the molecular level.
Reduced inflammatory cell infiltration, decreased collagen deposition in lung tissue, and suppressed the expression of key fibrosis markers (i.e., collagen I and α-SMA) in BLM-injured lung tissue.
化学情報
-
分子量 785.39
-
分子式 C40H37ClN4O5S3
-
SMILES
CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(OC5=CC=C(C=C5)OCCCCCCOC6=CC=C(C=C6)C7=CC(SS7)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz